表纸
市场调查报告书
商品编码
1028764

症候群多重诊断市场:Covid-19 影响、策略和趋势:症候群(呼吸、脓毒症、胃肠道等)、位置、产品、国家预测:市场分析、执行指南和定制(2021 年)~2025 年)

Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Place, by Product and by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025

出版日期: | 出版商: Howe Sound Research | 英文 501 Pages | 商品交期: 最快1-2个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

COVID 大流行预示著传染病诊断新世界的到来。传染病诊断正在发生变化,并将继续发生变化。

市场上正在展示症候群测试。市场进入者报告了两位数的增长。它有助于降低成本、改善治疗效果并对抗抗菌素耐药性。

本报告探讨了症候群多重诊断市场,并按症候群、位置、产品、国家和进入市场的公司概况提供了市场概况以及趋势。

目录

第 1 章市场指南

  • COVID 影响的情况分析和概述
  • 高管和营销人员指南
  • 投资分析师和管理顾问指南
  • 大公司的市场份额-表格和图表

第 2 章市场的介绍和定义

  • 什么是症候群多重测试?
  • 症候群检测——诊断领域的一场悄然革命
    • 症候群测试
  • 市场定义
    • 多元市场规模
    • 货币
  • 调查方法
    • 作者
    • 来源
  • 前景:医疗保健、IVD 行业和 COVID-19 大流行
    • 全球医疗保健支出
    • 诊断费用
    • 保险对诊断的重要作用

第 3 章传染病-病原体指南

  • 冠状病毒
    • 严重急性呼吸系统综合症 (SARS)
    • 中东呼吸症候群 (MERS)
    • COVID-19
  • HIV-人类免疫缺陷病毒 (AIDS)
    • 病毒学
    • 诊断
    • 检验
  • HBV-B 型肝炎
    • 病毒学
    • 机制
    • 诊断
    • 市场机会分析
  • HCV-C 型肝炎
    • 分类方法
    • 分子生物学
    • 复制
    • 基因型
    • 市场机会分析
  • 2.4HPV-人乳头瘤病毒
    • 病毒学
    • 诊断
    • 市场机会分析
  • 流感
    • 病毒学
    • 检验
    • 市场机会分析
  • CTGC-衣原体/淋病
    • 淋病
    • 衣原体
    • 检验
    • 市场机会分析
  • 结核病
    • 分枝杆菌
    • 诊断
    • 流行病学
    • 分子诊断测试
    • 市场机会分析
  • MRSA-耐甲氧西林金黄色葡萄球菌
    • 诊断
    • FDA 批准的分子检测
    • 市场机会分析
  • VRE-万古霉素耐药肠球菌
    • FDA 批准的 VRE 分子诊断测试
    • 市场机会分析

第 4 章行业概况

  • 行业参与者
    • IVD 供应商
    • 独立实验室:专业/难点领域
    • 独立实验室:国家/地区
    • 独立实验室:分析
    • 公共国家/地区研究所
    • 医院实验室
    • 从业者实验室
    • 审计机构
  • 临床检测细分市场
    • 传统的市场细分
    • 实验室重点和细分
    • 症状测试市场细分
  • 产业结构
    • 医院检查分享
    • 规模经济
    • 从业者实验室
    • 医生和 POCT

第 5 章市场趋势

  • 生长促进因素
    • 诊断速度
    • 症候群测试对成本的影响
    • 护理点的好处
    • 综合测试、准确性和诊断风险
    • 1 次访问
    • 改善结果
    • COVID-19 大流行的影响
  • 生长抑制因素
    • 低价
    • 管理/赎回
    • 减少传染病
    • 健康危害
    • 通过经济增长提高生活水平
    • 大流行性衰退的影响
  • 仪器仪表和自动化
    • 设备是市场份额的关键
    • 收缩器
    • 症候群测试会转移到更大的设备上吗?
  • 诊断技术的发展
    • Syndromictrends.com
    • 症候群与靶向检测的比较
    • 多重范式转变
    • 脓毒症检测市场-症候群领导者
    • 一次就诊与抗菌性
    • 症候群测试促进 POCT 的采用
    • PCR 的大未来

第 6 章症候群测试-最新进展

第 7 章主要症状检测公司简介

第 8 章世界症候群多重诊断市场

  • 按国家/地区分列的全球市场概览
    • Table-World Markets by Country
    • 图表-按国家/地区划分的世界市场
  • World Market-By Syndrome-概览
    • Table-World Market-By 症候群
    • 图表-世界市场-按症候群-标准/最后一年比较
    • 图表-世界市场-按症候群-基年
    • 图表-世界市场-按症候群-年末
    • 图表-世界市场-按症候群-按年份额
    • Chart-World Marketplace-By Syndrome-Segment Growth
  • 世界市场-按位置-概览
    • Table-World Markets-By Location
    • 图表-世界市场-按位置-标准/最后一年比较
    • 图表-世界市场-按位置-基准年
    • 图表-世界市场-按地点-年末
    • 图表-世界市场-按位置-按年份额
    • 图表-世界市场-按位置-细分市场增长
  • 按产品分类的全球市场概览
    • Table-World Market-By Product
    • 图表-世界市场-按产品-标准/去年比较
    • 图表-世界市场-按产品-基准年
    • 图表-世界市场-按产品-年末
    • 图表-世界市场-按产品-年份额
    • 图表世界市场-按产品细分市场增长

第 9 章世界症候群多重市场-按症候群

  • 呼吸系统
  • 胃肠道
  • 脑膜炎/脑炎
  • 性传播疾病
  • 其他

第 10 章世界症候群多市场-按位置

  • 医院实验室
  • 门诊实验室
  • 概念验证
  • 其他

第 11 章全球症候群多重市场-副产品

  • 设备
  • 墨盒
  • 试剂
  • 其他

第 12 章附录

目录

OVERVIEW:

The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2025. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis & COVID Impact Overview
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 What are Syndromic Multiplex Tests?
  • 2.2 Syndromic Testing - the quiet revolution in diagnostics
    • 2.2.1 Syndromic Testing - more than Panels
  • 2.3 Market Definition
    • 2.3.1 Multiplex Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 The Coronavirus
    • 3.1.1 Severe acute respiratory syndrome (SARS)
    • 3.1.2 Middle East respiratory syndrome (MERS)
    • 3.1.3 COVID-19. The SARS CoV 2 Virus
      • 3.1.3.1 Signs and symptoms
      • 3.1.3.2 Transmission
      • 3.1.3.3 Diagnosis
      • 3.1.3.4 Prevention
      • 3.1.3.5 Management
      • 3.1.3.6 Prognosis
      • 3.1.3.7 New Strains and Subsequent Mutations
  • 3.3 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.3.1 Virology
      • 3.3.1.1 Classification
      • 3.3.1.2 Structure and genome
      • 3.3.1.3 Tropism
      • 3.3.1.4 Replication cycle
      • 3.3.1.5 Genetic variability
    • 3.3.2 Diagnosis
    • 3.3.3 Testing
      • 3.3.3.1 Antibody tests
      • 3.3.3.2 Point of Care Tests (POCT)
      • 3.3.3.3 Antigen Tests
      • 3.3.3.4 Nucleic acid-based tests (NAT)
      • 3.3.3.5 Other tests used in HIV treatment
  • 3.4 HBV - Hepatitis B
    • 3.4.1 Virology
      • 3.4.1.1 Genome
      • 3.4.1.2 Pathogenesis
      • 3.4.1.3 Hepatitis B virus replication
      • 3.4.1.4 Serotypes and genotypes
    • 3.4.2 Mechanisms
    • 3.4.3 Diagnosis
    • 3.4.4 Market Opportunity Analysis
  • 3.5 HCV - Hepatitis C
    • 3.5.1 Taxonomy
      • 3.5.1.1 Structure
      • 3.5.1.2 Genome
    • 3.5.2 Molecular biology
    • 3.5.3 Replication
    • 3.5.4 Genotypes
      • 3.5.4.1 Clinical importance
    • 3.5.5 Market Opportunity Analysis
  • 3.6 2.4 HPV - Human papillomavirus
    • 3.6.1 Virology
      • 3.6.1.1 E6/E7 proteins
      • 3.6.1.2 Role in cancer
      • 3.6.1.3 E2 research
      • 3.6.1.4 Latency period
      • 3.6.1.5 Clearance
    • 3.6.2 Diagnosis
      • 3.6.2.1 Cervical testing
      • 3.6.2.2 Oral testing
      • 3.6.2.3 Testing men
      • 3.6.2.4 Other testing
    • 3.6.3 Market Opportunity Analysis
  • 3.7 Influenza
    • 3.7.1 Virology
      • 3.7.1.1 Types of virus
      • 3.7.1.2 Influenzavirus A
      • 3.7.1.3 Influenzavirus B
      • 3.7.1.4 Influenzavirus C
      • 3.7.1.5 Structure, properties, and subtype nomenclature
      • 3.7.1.6 Replication
    • 3.7.2 Testing
      • 3.7.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.7.3 Market Opportunity Analysis
  • 3.8 CTGC - Chlamydia/Gonorhea
    • 3.8.1 Gonorrhea
      • 3.8.1.1 Diagnosis
      • 3.8.1.2 Screening
    • 3.8.2 Chlamydia
      • 3.8.2.1 Diagnosis
      • 3.8.2.2 Screening
    • 3.8.3 Testing
      • 3.8.3.1 Nucleic acid amplification tests (NAATs)
      • 3.8.3.2 Performance of NAAT Tests
    • 3.8.4 Market Opportunity Analysis
  • 3.9 Tuberculosis
    • 3.9.1 Mycobacteria
    • 3.9.2 Diagnosis
      • 3.9.2.1 Active tuberculosis
      • 3.9.2.2 Latent tuberculosis
    • 3.9.3 Epidemiology
    • 3.9.4 Molecular Diagnostic Tests
    • 3.9.5 Market Opportunity Analysis
  • 3.10 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.10.1 Diagnosis
    • 3.10.2 FDA Approved Molecular Tests
    • 3.10.3 Market Opportunity Analysis
  • 3.11 VRE - Vancomycin-resistant Enterococcus
    • 3.11.1 FDA Approved MDx Tests for VRE
    • 3.11.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Industry Participants
    • 4.1.1 IVD Supplier
    • 4.1.2 Independent lab specialized/esoteric
    • 4.1.3 Independent lab national/regional
    • 4.1.4 Independent lab analytical
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician lab
    • 4.1.8 Audit body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Speed of Diagnosis
    • 5.1.2 Effect of Syndromic Testing on Costs
    • 5.1.3 Point of Care Advantage
    • 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 5.1.5 Single Visits
    • 5.1.6 Improvement in Outcomes
    • 5.1.7 Impact of the COVID-19 Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Prices
    • 5.2.2 Administration/reimbursement
    • 5.2.3 Infectious Disease is Declining But...
    • 5.2.4 Wellness Hurts
    • 5.2.5 Economic Growth improves Living Standards
    • 5.2.6 Impact of the Pandemic Recession
  • 5.3 Instrumentation and Automation
    • 5.3.1 Instruments Key to Market Share
    • 5.3.2 The Shrinking Machine
    • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4 Diagnostic Technology Development
    • 5.4.1 Syndromictrends.com
    • 5.4.2 Comparing Syndrome and Targeted Testing
    • 5.4.3 The Multiplex Paradigm Shift
    • 5.4.4 The Sepsis Testing Market - Bellwether for Syndromics
    • 5.4.5 The Single Visit and AntiMicrobial Resistance
    • 5.4.6 Syndromics drives POCT adoption
    • 5.4.7 A Big Future for PCR?

6 Syndromic Testing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 QuantuMDx Developing Syndromic Panels for European Launch
  • 6.3 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
  • 6.4 QuantumDx Gets CE Mark for Rapid PoC PCR System
  • 6.5 Bio-Rad Laboratories, Seegene Partner for MDx Development
  • 6.6 Baebies to Expand Finder Platform
  • 6.7 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
  • 6.8 Binx Health Targeting Clinics, DTC & OTC With STI Tests
  • 6.9 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
  • 6.10 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
  • 6.11 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
  • 6.12 New Approach Involves Silicon-Based Test for Infectious Disease Screening
  • 6.13 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • 6.14 Qiagen sees NeuMoDx as Growth Vehicle
  • 6.15 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • 6.16 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • 6.17 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • 6.18 Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • 6.19 ChromaCode Raises Additional $10M
  • 6.20 COVID-19 Patients Need Syndromic Testing
  • 6.21 GenMark Diagnostics - New Respiratory Panel due in June
  • 6.22 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • 6.23 Exact Diagnostics launches respiratory panel control
  • 6.24 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • 6.25 Nanomix Receives CE Mark for Diagnostic
  • 6.26 Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • 6.27 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • 6.28 QIAGEN's New GI Panel Performance Assessed
  • 6.29 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • 6.30 Applied BioCode Obtains FDA Clearance
  • 6.31 Meridian Bioscience to Acquire GenePOC Inc
  • 6.32 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • 6.33 Qiagen gets FDA clearance for syndromic testing system
  • 6.34 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • 6.35 Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • 6.36 Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • 6.37 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • 6.38 QuantuMDx and Molbio announce MoU
  • 6.39 Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • 6.40 Mobidiag Inks European, Middle Eastern Distribution Deals
  • 6.41 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial

7 Profiles of Key Syndromic Testing Companies

  • 7.1 Abacus Diagnostica
  • 7.2 Abbott Diagnostics
  • 7.3 Accelerate Diagnostics
  • 7.4 Ador Diagnostics
  • 7.5 Akonni Biosystems
  • 7.6 Alveo Technologies
  • 7.7 Antelope Dx
  • 7.8 Applied BioCode
  • 7.9 Aus Diagnostics
  • 7.10 Baebies
  • 7.11 Beckman Coulter Diagnostics
  • 7.12 Becton, Dickinson and Company
  • 7.13 Binx Health
  • 7.14 Biocartis
  • 7.15 BioFire Diagnostics (bioMérieux)
  • 7.16 bioMérieux Diagnostics
  • 7.17 Bio-Rad Laboratories, Inc
  • 7.18 Bosch Healthcare Solutions GmbH
  • 7.19 Cepheid (Danaher)
  • 7.20 Credo Diagnostics Biomedical
  • 7.21 Cue Health
  • 7.22 Curetis N.V. / Curetis GmbH
  • 7.23 Diagenode Diagnostics
  • 7.24 Diasorin S.p.A
  • 7.25 Enzo Life Sciences, Inc
  • 7.26 Eurofins Scientific
  • 7.27 Fluxergy
  • 7.28 Fusion Genomics
  • 7.29 Genetic Signatures
  • 7.30 GenMark Dx (Roche)
  • 7.31 Hibergene Diagnostics
  • 7.32 Hologic
  • 7.33 Immunexpress
  • 7.34 Inflammatix
  • 7.35 Invetech
  • 7.36 Janssen Diagnostics
  • 7.37 Karius
  • 7.38 Lexagene
  • 7.39 LightDeck Diagnostics
  • 7.40 Lucira Health
  • 7.41 Luminex Corp
  • 7.42 Maxim Biomedical
  • 7.43 Meridian Bioscience
  • 7.44 Mesa Biotech (Thermo Fisher)
  • 7.45 Millipore Sigma
  • 7.46 Mobidiag (Hologic)
  • 7.47 Molbio Diagnostics
  • 7.48 Nanomix
  • 7.49 Novel Microdevices
  • 7.50 Operon
  • 7.51 Oxford Nanopore Technologies
  • 7.52 Panagene
  • 7.53 Perkin Elmer
  • 7.54 Primerdesign (Novacyt)
  • 7.55 Prominex
  • 7.56 Qiagen Gmbh
  • 7.57 Quantumdx
  • 7.58 Quidel
  • 7.59 Roche Molecular Diagnostics
  • 7.60 Saw Diagnostics
  • 7.61 Seegene
  • 7.62 Siemens Healthineers
  • 7.63 Sona Nanotech
  • 7.64 SpeeDx
  • 7.65 T2 Biosystems
  • 7.66 Talis Biomedical
  • 7.67 Thermo Fisher Scientific Inc
  • 7.68 Veramarx
  • 7.69 Visby Medical
  • 7.70 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Place - Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth
  • 8.4 Global Market by Product - Overview
    • 8.4.1 Table - Global Market by Product
    • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Product - Base Year
    • 8.4.4 Chart - Global Market by Product - End Year
    • 8.4.5 Chart - Global Market by Product - Share by Year
    • 8.4.6 Chart - Global Market by Product - Segments Growth

9 Global Syndromic Multiplex Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other Syndrome
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Infectious Disease Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other - by Country
    • 10.4.2 Chart - Other Place Growth

11 Global MDx Infectious Disease Markets - by Product

  • 11.1 Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 Cartridges
    • 11.2.1 Table Cartridges - by Country
    • 11.2.2 Chart - Cartridges Growth
  • 11.3 Reagents
    • 11.3.1 Table Reagents - by Country
    • 11.3.2 Chart - Reagents Growth
  • 11.4 Other Product
    • 11.4.1 Table Other Product - by Country
    • 11.4.2 Chart - Other Product Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Characteristics of Coronavirus Pandemic Infections
  • Table 3 COVID-19 Symptoms
  • Table 4 Classification of HIV Species
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 Influenza Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 Market Players by Type
  • Table 23 Clinical Laboratory Departments and Segments
  • Table 24 Laboratory Management Focus - Different Approaches
  • Table 25 Key Segmentation Variables Going Forward
  • Table 26 Possible Market Segments of Syndromic Multiplex Market
  • Table 27 Five Factors Driving Growth
  • Table 28 How SMT Improves Outcomes
  • Table 29 Four Factors Limiting Growth
  • Table 30 - Global Market by Region
  • Table 31 Global Market by Syndrome
  • Table 32 Global Market by Place
  • Table 33 Global Market by Product
  • Table 34 Respiratory by Country
  • Table 35 Gastrointestinal by Country
  • Table 36 Blood by Country
  • Table 37 Meningitis/Encephalitis by Country
  • Table 38 Sexually Transmitted Disease by Country
  • Table 39 Other by Country
  • Table 40 Hospital Lab by Country
  • Table 41 Outpatient Lab by Country
  • Table 42 Point of Care by Country
  • Table 43 Other by Country
  • Table 44 Instruments by Country
  • Table 45 Cartridges by Country
  • Table 46 Reagents by Country
  • Table 47 Other Product by Country
  • Table 48 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 The Global Healthcare Spending Picture
  • Figure 3 The Lab Test Pie
  • FIGURE 4 STRUCTURE OF CORONAVIRUSES
  • Figure 5 HIV Virion
  • Figure 6 Diagram of the HIV Replication Cycle
  • Figure 7 The Structure of the HBV Virus
  • Figure 8 Hepatitis B Replication
  • Figure 9 Structure of the HCV Virus
  • Figure 10 HCV Replication Cycle
  • Figure 11 Structure of the Influenza Virion
  • Figure 12 Influenza Replication
  • Figure 13 Scanning Electronmicrograph of Tuberculosis
  • Figure 14 Chart Death Rates and Infectious Disease Decline
  • Figure 15 Comparing Syndromic and Targeted Testing
  • Figure 16 The Multiplex Paradigm Shift
  • Figure 17 Global Market Share Chart
  • Figure 18 Global Market by Syndrome - Base vs. Final
  • Figure 19 Global Market by Syndrome Base Year
  • Figure 20 Global Market by Syndrome End Year
  • Figure 21 Syndrome Share by Year
  • Figure 22 Syndrome Segments Growth
  • Figure 23 Global Market by Place - Base vs. Final
  • Figure 24 Global Market by Place Base Year
  • Figure 25 Global Market by Place End Year
  • Figure 26 Place Share by Year
  • Figure 27 Place Segments Growth
  • Figure 28 Global Market by Product - Base vs. Final
  • Figure 29 Global Market by Product Base Year
  • Figure 30 Global Market by Product End Year
  • Figure 31 Product Share by Year
  • Figure 32 Product Segments Growth
  • Figure 33 Respiratory Growth
  • Figure 34 Gastrointestinal Diagnostics Growth
  • Figure 35 Blood Growth
  • Figure 36 Meningitis/Encephalitis Growth
  • Figure 37 Sexually Transmitted Disease Growth
  • Figure 38 Other Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 Point of Care Growth
  • Figure 42 Other Growth
  • Figure 43 Instruments Growth
  • Figure 44 Cartridges Growth
  • Figure 45 Reagents Growth
  • Figure 46 Other Product Growth